Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer

ClinicalTrials.gov ID: NCT02339558

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02339558. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multicenter Phase II Study of Nivolumab in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of improvement (recurrent) and/or has spread to other parts of the body (metastatic). Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.

Study identification

NCT ID: NCT02339558
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: National Cancer Institute (NCI); NIH
Enrollment: 45 participants

Conditions and interventions

Conditions

Interventions

Laboratory Biomarker Analysis Other
Nivolumab Biological

Other · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 28, 2015 (Actual)
Primary completion: Jun 16, 2018 (Actual)
Completion: Mar 21, 2019 (Actual)
Last update posted: Nov 10, 2026

2015 – 2019

United States locations

U.S. sites: 15
U.S. states: 6
U.S. cities: 11

Facility	City	State	ZIP	Site status
City of Hope Comprehensive Cancer Center	Duarte	California	91010	—
Los Angeles County-USC Medical Center	Los Angeles	California	90033	—
USC / Norris Comprehensive Cancer Center	Los Angeles	California	90033	—
Keck Medical Center of USC Pasadena	Pasadena	California	91105	—
University of California Davis Comprehensive Cancer Center	Sacramento	California	95817	—
City of Hope South Pasadena	South Pasadena	California	91030	—
Moffitt Cancer Center	Tampa	Florida	33612	—
Northwestern University	Chicago	Illinois	60611	—
University of Chicago Comprehensive Cancer Center	Chicago	Illinois	60637	—
UC Comprehensive Cancer Center at Silver Cross	New Lenox	Illinois	60451	—
University of Maryland/Greenebaum Cancer Center	Baltimore	Maryland	21201	—
Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore	Maryland	21287	—
Mayo Clinic Cancer Center P2C	Rochester	Minnesota	55905	—
Mayo Clinic	Rochester	Minnesota	55905	—
Washington University School of Medicine	St Louis	Missouri	63110	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02339558, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 10, 2026 · Synced Nov 15, 2026